stockrowCelcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
Follow CELC
Alert me
Celcuity, Inc. (CELC) Return on invested capital
Celcuity, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −14,733.4% (fiscal 2022) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 14,733.36 |
| FY2022 | −14,733.4% | (14,733.36) |
| FY2021 | 0.00% | 8,215.44 |
| FY2020 | −8,215.4% | (7,369.54) |
| FY2019 | −845.9% | 204.48 |
| FY2018 | −1,050.4% | (998.31) |
| FY2017 | −52.1% | (52.07) |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.00% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| DNLI Denali Therapeutics Inc. compare | −80.0% |
| IDYA IDEAYA Biosciences, Inc. compare | −114.2% |
| DYN Dyne Therapeutics, Inc. compare | −1,956.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)